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It is unclear whether homocysteine itself is causal in the pathogenesis of
cardiovascular disease. Alternatively or additionally, the association between homo-
cysteine and cardiovascular disease may be because of its metabolic precursor, S-
adenosylhomocysteine, or of the ratio of S-adenosylmethionine to S-adenosylhomocysteine.
Therefore, it is relevant to know how these moieties are interrelated, and whether, as is the








We cross-sectionally studied a population-based cohort of 97 Caucasian sub-
jects aged 60–85 years. Concentrations of homocysteine, S-adenosylhomocysteine, S-






































 increase in erythrocyte folate, change





















S-adenosylmethionine and the ratio of S-adenosylmethionine to S-adenosylhomocysteine
were not associated with serum folate, cobalamin or vitamin B6, nor with erythrocyte folate.
Furthermore, plasma homocysteine showed a negative correlation with the ratio of S-

















In contrast to homocysteine, the plasma concentrations of S-
adenosylhomocysteine and the ratio of S-adenosylmethionine to S-adenosylhomocysteine
were not associated with the folate, cobalamin and vitamin B6 concentrations in the present
study. If these precursors in part explain why homocysteine is associated with cardiovascular
disease, homocysteine-lowering treatment with B vitamins may be less effective than




Cardiovascular disease, cobalamin, folate, homocysteine, intervention trials,
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Hyperhomocysteinemia is an independent risk factor for
cardiovascular disease [1–3]. This suggests that treatment





decrease plasma homocysteine, may be beneficial [4–9].
Accordingly, large clinical trials have been initiated to test
this hypothesis [10], and two randomized, controlled trials
with intermediate endpoints have already been published
[11,12].
However, it remains unclear whether homocysteine
itself is causal in the pathogenesis of cardiovascular disease.
Alternatively or additionally, the association between
homocysteine and cardiovascular disease may result from
its metabolic precursor, S-adenosylhomocysteine [13–16]
or from the ratio of S-adenosylmethionine (the precursor
of S-adenosylhomocysteine) to S-adenosylhomocysteine
[17,18]. This contention is based on the known effects of
these moieties on cellular methylation, disturbances of
which may lead to endothelial dysfunction and/or cardio-
vascular disease [13–15,18]. Thus, it is relevant to know
how these moieties are interrelated, and how they relate to
B vitamin status. Such data, however, are scarcely available
[19].
The aim of this study was to investigate, in an elderly
population, the associations between, on the one hand,
homocysteine, S-adenosylhomocysteine, and the ratio of
S-adenosylmethionine to S-adenosylhomocysteine and,
on the other hand, blood levels of B vitamins. We did not







The Hoorn Study is a longitudinal population-based study
addressing glucose intolerance and related complications. It
was started in 1989 and consisted of Caucasian men and
women aged 50–75 years, as described in detail elsewhere
[20]. In the year 2000 these subjects were again invited to
partake in the study. For the present cross-sectional study
we focused only on 97 participants without type 2 diabetes,
randomly selected from this population. All participants
gave informed consent for this study, which was approved




Subjects were invited to the Hoorn study centre after an
overnight fasting period. We measured each subject’s blood
pressure, weight and height, and calculated their body mass
index and waist-to-hip ratio, as previously described [20].
We drew blood samples for the measurement of homo-
cysteine and its precursors: B vitamins, lipids (total choles-
terol, high-density-lipoprotein cholesterol, triacylglycerol),
creatinine and haematocrit. We estimated creatinine clear-
ance according to the Cockroft-Gault formula [21]. Hyper-
tension was defined according to the criteria of the Dutch
Society of General Practitioners that was in use when these









 95 mmHg, and/or the
use of antihypertensive medication [22]. Information on
pre-existent cardiovascular diseases (myocardial infarction,
angina pectoris, stroke and peripheral atherosclerotic dis-
ease) was obtained from the subjects using a translated ver-






















C), and analyzed within 3 months. After collection,
ethylenediaminetetraacetic acid (EDTA)-anticoagulated
blood samples were placed on ice for the determination of
homocysteine, S-adenosylmethionine and S-adenosylho-
mocysteine. For S-adenosylmethionine and S-adenosylho-
mocysteine measurements, we deproteinized the samples
immediately by adding 0·625 mL of a 10% perchloric acid
solution to 1 mL of plasma and by adding 1 mL of 5% per-
chloric acid to 1 mL of whole blood, followed by mixing
[18]. We added 0·5 mg of ascorbic acid to 0·5 mL of serum
for the determination of total folate [18]. For the determi-
nation of total folate in erythrocytes, 1 mL of reagent with
ascorbic acid, human serum albumin and sodium azide
(ACS:180, Chiron Diagnostics, Fernwald, Germany) was




L of whole blood.
 




Total plasma homocysteine was determined with an auto-
mated fluorescence polarisation immunoassay on an Abbott
IMx analyzer (Abbott Laboratories Ltd, IL, USA) (interassay
coefficient of variation, CV, 4%) [24]. We used tandem mass
spectrometry for the determination of S-adenosylmethio-
nine and S-adenosylhomocysteine in plasma, and the whole
blood, as previously described (intra-assay CV, 4% for both
determinations; interassay CV, 8% and 6%, respectively)
[25]. We measured total folate in the red blood cell haemolysate
and serum, and cobalamin in the serum by means of auto-




Automated Chemiluminescence System). The intraassay
and interassay CVs were 4% and 5% for total folate, respect-
ively, and 4% and 5% for cobalamin. Erythrocyte concen-
trations of the metabolites were calculated by multiplying
the difference between plasma or serum and the whole blood






. We used high-performance





based on precolumn semicarbazone formation and fluores-
cence detection [26]. The interassay CV was 7%.
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Determination of lipids and creatinine
 
We determined serum total cholesterol, HDL cholesterol
and triglycerides by enzymatic techniques (Boehringer-
Mannheim, Mannheim, Germany) and serum creatinine by




All analyses were performed with SPSS 10·1 for Windows
95 (SPSS, Chicago, IL, USA). Because the distributions of
homocysteine, most of its metabolites and B vitamins were
positively skewed, we present medians and interquartile ranges
of these variables. We performed univariate and multivariate
linear regression analyses to determine associations between
homocysteine, or one of its precursors, and B vitamins. In





were calculated (model 1). In model 2 we used multivariate




 coefficients for each B vitamin
after mutual adjustment for the other two B vitamins. The
final model [3] was model 2 with additional adjustment for
other possible determinants. In all models we regarded
homocysteine, S-adenosylhomocysteine, S-adenosylme-
thionine or the ratio of S-adenosylmethionine to S-adeno-
sylhomocysteine in plasma or erythrocytes as the dependent
variable, respectively. We did not use any log-transformed
data in the regression analyses because the determinants
had a linear relation with each outcome variable. We calcu-
lated which folate measurement (total folate in serum or
total folate in erythrocytes) had the strongest association with
the respective dependent variables in model 1 by log-trans-
forming these measurements of folate status and comparing
changes in homocysteine associated with a 10% increase in
each folate measure. In models 2 and 3, we added the folate
measure with the strongest association with the dependent
variable. In model 3, we added age, sex, creatinine clearance,
lipids, hypertension, body mass index and waist-to-hip ratio
as possible determinants [2,27–30]. Pearson correlation
coefficients were calculated to determine the association
between homocysteine and S-adenosylmethionine, S-ade-
nosylhomocysteine or the ratio of S-adenosylmethionine
and S-adenosylhomocysteine in plasma and erythrocytes,





General characteristics [Table 1]
 










) was present in 16·5% of the population [1]. Con-




, cobalamin and folate in serum
were below the reference range in four, five and two subjects,
respectively. Total folate concentrations in erythrocytes was
within the range as described by the assay’s manufacturer.
The ratio of S-adenosylmethionine to S-adenosylhomocysteine
was significantly higher in erythrocytes than in plasma
(24·9 vs. 6·24). The ranges of plasma concentrations of
S-adenosylmethionine and S-adenosylhomocysteine were
comparable with the ranges in three studies of similarly aged
subjects [16–18]. The range of S-adenosylmethionine
concentrations in erythrocytes was similar to that in two





. [13]. The range of S-adenosylhomocysteine
in erythrocytes was somewhat lower than in a previous study
[18]. That study was, however, based on a group of only
50, healthy, participants.
 
Determinants of homocysteine [Table 2]
 
As expected, the univariate linear regression analyses
showed that vitamin B6, cobalamin and folate in serum
and erythrocytes had a significant negative association with
the homocysteine. Total folate in erythrocytes was the
folate measure with the strongest association with homo-
cysteine. When the concentration of folate in erythrocytes
increased by 10%, the concentration of the homocysteine




















for folate in serum. In the multivariate regression ana-
lyses, folate in erythrocytes and cobalamin remained
significant determinants of homocysteine, even after
adjustment for possible confounders (model 3). Lipid con-
centrations, hypertension and waist-to-hip ratio did not
influence the regression coefficients of the B vitamins (data
not shown). In addition, sex, creatinine clearance and the
body mass index were significantly associated with the
homocysteine.
 
Determinants of S-adenosylhomocysteine and 
the ratio of S-adenosylmethionine to 
S-adenosylhomocysteine [Table 2]
 
S-adenosylhomocysteine, S-adenosylmethionine and their
ratio in plasma were not significantly associated with folate
in the univariate analyses. For the multivariate analyses, the
measurement of folate status (plasma or erythrocyte) that
was least weakly associated with the dependent variable of
interest was used (see Table 2).
Neither in the univariate nor multivariate regression analyses
were S-adenosylhomocysteine, S-adenosylmethionine or the
ratio of S-adenosylmethionine to S-adenosylhomocysteine
in the plasma significantly associated with any B vitamin.
In contrast, these variables in plasma were significantly
associated with sex, creatinine clearance and body mass
index, except for S-adenosylmethionine, which was associ-
ated only with the body mass index. Lipid concentrations,
hypertension and waist-to-hip ratio did not influence the
regression coefficients of the B vitamins (data not shown).
In erythrocytes, no significant association was found
between S-adenosylhomocysteine or the ratio of S-
adenosylmethionine to S-adenosylhomocysteine on the one
hand, and any B vitamin, sex, creatinine clearance or body
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Correlations among homocysteine, 
S-adenosylmethionine, S-adenosylhomocysteine 
and their ratio [Table 3]
 
Homocysteine had a significant negative correlation with the
ratio of S-adenosylmethionine to S-adenosylhomocysteine
in plasma, but not in erythrocytes. S-adenosylmethionine
and S-adenosylhomocysteine in plasma, but not in









Adjustment for age, sex and creatinine clearance did not
materially affect any of these univariate correlations (data
not shown). Figure 1 depicts the relations between S-
adenosylmethionine and S-adenosylhomocysteine in plasma
and in erythrocytes, and between the homocysteine level and





This population-based study is the first to show that, in
contrast to homocysteine, plasma concentrations of S-
adenosylhomocysteine and the ratio of S-adenosylmethionine
to S-adenosylhomocysteine are not associated with concen-




 in an elderly
population. Furthermore, our results showed that, in this
elderly population, creatinine clearance, body mass index
and sex were determinants not only of homocysteine,
but also of S-adenosylhomocysteine, and the ratio of
S-adenosylmethionine to S-adenosylhomocysteine in
plasma. Homocysteine showed a negative correlation
with the ratio of S-adenosylmethionine to S-adenosylhomo-
cysteine in plasma, but not in erythrocytes. In fact, the
erythrocyte concentrations of S-adenosylmethionine and
Table 1 Characteristics of the participants (n = 97)
  
  
Mean (SD‡), median (IQR*) or percentage Range
Age (years) 70·5 (6·4) 60–85
Gender (% male) 56·7
Body mass index 26·3 (3·5) 20·5–42·8
Waist-to-hip ratio
Men 0·99 (0·09) 0·89–1·50
Women 0·85 (0·07) 0·69–0·96
Systolic blood pressure (mmHg) 143·6 (19·5) 100–195
Diastolic blood pressure (mmHg) 84·6 (11·3) 56–113
Hypertension (%) 41·2
Cardiovascular disease (%) 23·7
Plasma or serum value
Creatinine (µmol L−1) 96·7 (14·6) 59–149
Creatinine clearance (mL min−1)†
Men 69·3 (13·1) 37–112
Women 58·6 (12·2) 40–101
Total cholesterol (mmol L−1) 5·84 (0·90) 4·0–8·8
HDL-cholesterol (mmol L−1) 1·45 (0·40) 0·8–3·4
Triglycerides (mmol L−1) 1·3 (0·93–1·7) 0·5–5·0
Homocysteine (nmol L−1)
Men (9·3–14·4) 5·8–38·5
Women 11·0 (9·8–13·8) 5·7–24·4
Vitamin B6 (nmol L
−1) 36·0 (24·5–51·0) 10–455
Cobalamin (pmol L−1) 266 (210–318) 22–626
Folate (nmol L−1) 15·0 (11·0–19·2) 3·0–45·4
S-adenosylmethionine (nmol L−1) 97·3 (83·9–108·0) 53–208
S-adenosylhomocysteine (nmol L−1) 15·6 (12·6–18·8) 6·6–32·7
SAM/SAH ratio§ 6·24 (5·29–6·99) 3·6–11·2
Erythrocyte value
Folate (nmol/L) 551 (423–663) 158–1222
S-adenosylmethionine (nmol L−1) 3523 (3049–3950) 2376–5107
S-adenosylhomocysteine (nmol L−1) 132 (113–164) 71–522
SAM/SAH ratio§ 24·9 (20·8–31·8) 4·6–54·4
*Interquartile range.
†Estimated by the Cockcroft-Gault formula.
‡Standard deviation.
§SAM/SAH ratio = ratio of S-adenosylmethionine and S-adenosylhomocysteine; reference ranges.
Vitamin B6, 17–100 nmol L
−1; cobalamin, 156–672 pmol L−1; folate in serum, > 6·5 nmol L−1; folate in erythrocytes, 125–2500 nmol L−1; 
S-adenosylmethionine in plasma 34·8–79·5 nmol L−1; S-adenosylmethionine in erythrocytes 2701–5344 nmol L−1; 
S-adenosylhomocysteine in plasma 11·8–39·4 nmol L−1; S-adenosylhomocysteine in erythrocytes 128–328 nmol L−1 (generally accepted 
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Cobalamin (per 50 pmol L−1) −0·75 (−1·35 to −0·15) 0·14 (−0·46–0·74) 2·47 (−0·53–5·47) 0·08 (−0·12–0·28)
Folate serum (per 10 nmol L−1) −1·76 (−3·10 to −0·42) −0·76 (−2·26–0·74) 0·44 (−6·67–7·54) 0·34 (−0·08–0·76)
Folate erythrocytes (per 100 nmol L−1) −0·83 (−1·43 to −0·23) 0·01 (−0·59–0·61) 0·62 (−2·18–3·42) −0·01 (−0·21−0·19)
Model 2
Vitamin B6 (per 10 nmol L
−1) −0·14 (−0·54–0·26) −0·10 (−0·38–0·18) −1·68 (−3·90–0·54) 0·04 (−0·04–0·12)
Cobalamin (per 50 pmol L−1) −0·65 (−1·25 to −0·05) 0·29 (−0·41–0·99) 2·78 (−0·42–5·98) 0·02 (−0·18–0·22)
Folate (per 10 or 100 nmol L−1)† −0·70 (−1·30 to −0·10) −5·30 (−23·5–12·90) 1·78 (−1·42–4·98) 1·72 (−3·28–6·72)
Model 3
Vitamin B6 (per 10 nmol L
−1) −0·21 (−0·61−0·19) −0·08 (−0·32–0·16) −1·12 (−3·34–1·10) 0·04 (−0·02–0·10)
Cobalamin (per 50 pmol L−1) −0·70 (−1·30 to −0·10) 0·40 (−0·20–1·0) 1·81 (−1·59–1·10) 0·08 (−0·28–0·13)
Folate (per 10 or 100 nmol L−1)† −0·68 (−1·28 to −0·08) −5·60 (−21·20–10·0) 2·0 (−1·20–5·20) 2·11 (−1·89–6·11)
Age (per 10 years) −1·79 (−3·79–0·21) 0·54 (−1·50–2·58) 1·91 (−8·97–12·79) −0·07 (−0·59–0·45)
Sex (female vs. male) −2·52 (−4·81 to −0·23) −5·11 (−7·38 to −2·83) 5·74 (−6·63–18·12) 2·15 (1·56–2·74)
Creatinine clearance (per 10 mL min−1) −1·7 (−2·84 to −0·56) −2·49 (−3·65 to −1·33) −3·21 (−9·37−2·95) 0·65 (0·35–0·95)
Body mass index (per 1 kg m−2) 0·39 (0·02–0·75) 0·71 (0·34 –1·08) 2·25 (0·30–4·21) −0·11 (−0·15 to −0·07)
CI, confidence interval; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; SAM/SAH, S-adenosylmethionine to S-adenosylhomocysteine ratio.
Model 1: univariate regression analyses; Model 2: multivariate regression analyses; Model 3: as Model 2 with additional adjustment for age, sex, creatinine clearance and body mass index.
*Change in concentration of homocysteine, SAH, SAM and SAM/SAH per increment of each determinant.
†In the analysis with homocysteine and S-adenosylmethionine we added folate to the erythrocytes (expressed per 100 nmol L−1) and in the analysis with S-adenosylhomocysteine 
or SAM/SAH we added folate to the serum (expressed per 10 nmol L−1).
22 A. Becker et al.
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S-adenosylhomocysteine were not associated with any of
the variables studied.
Folate in erythrocytes and serum cobalamin, but not
vitamin B6 in plasma, were independently associated with
plasma homocysteine, but not with S-adenosylhomocysteine
or the ratio of S-adenosylmethionine to S-adenosylhomocysteine
in plasma or erythrocytes. The association between homo-
cysteine and folate and cobalamin in elderly subjects has
been reported previously [31,32]. However, in the Fram-
ingham study, plasma vitamin B6 also was an independent
significant determinant [31]. In several other studies, the
association between homocysteine and vitamin B6 dis-
appeared after adjustment for cobalamin [6,8,9].
Poirier et al. showed, although in a younger age group,
that dietary folate and vitamin B6 did not correlate with
erythrocyte values of the ratio of S-adenosylmethionine
to S-adenosylhomocysteine after adjustment for body
weight and age. Cobalamin was not measured in this study
[19]. In apparent contrast to these studies, Perna et al.
reported that in patients on haemodialysis, oral therapy
with methyltetrahydrofolate, the active form of folic acid
decreased homocysteine concentration and increased
the S-adenosylmethionine to S-adenosylhomocysteine
ratio [33]. The strength of baseline correlations between
B-vitamins and homocysteine concentration and the S-
adenosylmethionine to S-adenosylhomocysteine ratio was,
unfortunately, not reported. Another point to be made
about Perna’s observations is that renal insufficiency is
characterized by marked folate resistance [34], and the
findings may thus not apply to subjects without significant
renal disease. In conclusion, it appears difficult to predict
whether supplementation with vitamin B6, cobalamin or folate
will influence concentrations of S-adenosylhomocysteine, or
the ratio of S-adenosylmethionine to S-adenosylhomocysteine
in healthy subjects or vascular patients. This remains to be
determined in experimental studies of increased B vitamin
intake.
Creatinine clearance was an important determinant of
homocysteine, S-adenosylhomocysteine, and the ratio of
S-adenosylmethionine to S-adenosylhomocysteine in plasma.
An independent relation between homocysteine and renal
function is well established, although its mechanism is still
debated [32,35–37]. An association with creatinine clear-
ance has been reported once, although in univariate analysis
only, for plasma S-adenosylhomocysteine [18]. This may be
explained by the fact that S-adenosylhomocysteine can be
removed from plasma by the kidney [38,39].
Sex and body mass index were also significantly associ-
ated with plasma concentrations of homocysteine, S-
adenosylhomocysteine and the ratio of S-adenosylmethionine
to S-adenosylhomocysteine. This has been demonstrated before
for homocysteine only [8,32]. Plasma S-adenosylhomocysteine
and the ratio of S-adenosylmethionine to S-adenosyl-
homocysteine may be associated with body mass index and
sex by the same (largely unexplained) mechanisms as
homocysteine, for example through physical activity, insulin
sensitivity and sex hormones [28,40].
Finally, it appeared that S-adenosylhomocysteine and
S-adenosylmethionine correlated in plasma, but not in
erythrocytes. Furthermore, the plasma and erythrocyte
values of S-adenosylhomocysteine and S-adenosylmethionine
did not correlate. Homocysteine concentration correlated
only with the ratio of S-adenosylmethionine to S-adenosyl-
homocysteine in plasma. There is a disturbing lack of
insight into the regulation of metabolic fluxes of S-adenosyl-
methionine and S-adenosylhomocysteine from cells to
plasma. Concentrations of S-adenosylmethionine are prob-
ably lower in erythrocytes than in other cells, as erythrocytes
are the only type of cells that cannot remethylate homo-
cysteine [41]. One option is that S-adenosylmethionine
‘leaks’ from erythrocytes to plasma. However, we would
then expect a correlation between S-adenosylmethionine in
erythrocytes and plasma, which we did not find. Second, it
has been suggested that S-adenosylmethionine may be
exported from the liver, which has a high methionine meta-
bolism, for use in other tissues [42]. A third possibility is that
S-adenosylmethionine is exported from intestinal cells after
adenosylation of food-derived methionine. However, there
is no direct evidence supporting the latter concept. S-adenosyl-
homocysteine may exit from the cell when the binding
capacity to intracellular proteins is exceeded [39]. However,
the absence of a correlation between the erythrocyte and
plasma concentrations of S-adenosylhomocysteine in our
study argues against this theory. Finally, it is unknown
whether S-adenosylmethionine can be transmethylated to
S-adenosylhomocysteine in plasma. The correlation we
found between these variables in the plasma would support
this possibility. In summary, the regulation of metabolic
Table 3 Correlation coefficients among plasma homocysteine and S-adenosylhomocysteine, S-adenosylmethionine and the ratio of 
S-adenosylmethionine to S-adenosylhomocysteine in plasma and erythrocytes
  
Plasma Erythrocytes
SAH SAM SAM/SAH ratio SAH SAM SAM/SAH ratio
Homocysteine 0·14 −0·08 −0·27* 0·003 0·08 0·08
SAH plasma 0·68** 0·05 0·1
SAH erythrocytes −0·04
SAM erythrocytes −0·012
*P < 0·01; **P < 0·001. P-value of the Pearson correlation coefficient.
SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; SAM/SAH, ratio of S-adenosylmethionine and S-adenosylhomocysteine.
Metabolic precursors of homocysteine 23
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fluxes of S-adenosylmethionine and S-adenosylhomocysteine
is probably multifactorial. Further research is necessary to
study these mechanisms.
It is not fully clarified whether homocysteine, S-adenosyl-
homocysteine and (or) the ratio of S-adenosylmethionine
to S-adenosylhomocysteine is causal in the pathogenesis of
cardiovascular disease. Likewise, it is unknown whether
intracellular or plasma levels of S-adenosylmethionine
and S-adenosylhomocysteine are most relevant for vascular
damage. Recent studies suggest an important role for S-
adenosylhomocysteine [14–16]. Dayal et al. demonstrated
that the development of endothelial dysfunction in mice is
associated with increased concentrations of S-adenosylhomo-
cysteine and a decreased ratio of S-adenosylmethionine to
S-adenosylhomocysteine in liver and brain [15]. Lee et al.
showed an inhibitory effect of S-adenosylhomocysteine
on the regeneration of vascular endothelial cells, which pre-
disposes to atherosclerosis [14]. Furthermore, it has been
reported that in patients with peripheral arterial occlusive
disease, S-adenosylhomocysteine in plasma and in erythro-
cytes is increased and the ratio of S-adenosylmethionine
and S-adenosylhomocysteine is decreased [18]. In erythro-
cytes of patients with uraemia, similar findings have been
reported [13]. If S-adenosylhomocysteine, or the ratio of
S-adenosylmethionine to S-adenosylhomocysteine indeed
prove to be causal, at least in part, the effect of B vitamin
supplementation on cardiovascular disease may turn out
to be smaller than expected, as the B vitamin concen-
trations were unrelated to these variables in the present
study.
This study had some limitations. In the first place, the
study population consisted of individuals aged 60–85
years, all Caucasians. We do not know whether our
findings can be generalized to younger individuals or other
ethnic groups. However, there are two advantages in
studying this particular age group. First, low to low-
normal vitamin B6, cobalamin and folate concentrations are
common in the elderly [43–45]. Second, the homocysteine
concentration increases with age [8]. Therefore, wider
ranges of B vitamins and homocysteine concentrations
can be studied in the elderly. Another limitation may be
that we only measured fasting homocysteine concentra-
tions. Thus, we do not know whether the findings also
apply to nonfasting or postmethionine homocysteine
concentrations. Finally, the precision of creatinine
clearance estimation by the Cockroft-Gault formula is
inherently limited, which may have resulted in an under-
estimation of the strength of the correlations with renal
function.
In conclusion, as the B vitamin concentrations were
not determinants of S-adenosylhomocysteine or the
ratio of S-adenosylmethionine to S-adenosylhomocysteine
in the present study, it is uncertain whether B-supplements
will lower these possibly harmful intermediates of
homocysteine metabolism. If these precursors in part
explain why homocysteine is associated with cardio-
vascular disease, homocysteine-lowering treatment
with B vitamins may be less effective than currently
expected.
Figure 1 Scatterplot of (a) S-adenosylmethionine and 
S-adenosylhomocysteine in plasma, (b) S-adenosylmethionine 
and S-adenosylhomocysteine in erythrocytes, and (c) the ratio 
of S-adenosylmethionine to S-adenosylhomocysteine and 
homocysteine in plasma; r, Pearson correlation coefficient; P-value 
corresponding to the Pearson correlation coefficient.
24 A. Becker et al.
© 2003 Blackwell Publishing Ltd, European Journal of Clinical Investigation, 33, 17–25
Acknowledgements
We are grateful to Ms Paula Sekeris, Ms Carine Bocxe-Maat
and Ms Hilde Hopman-Kerkhoff for their accurate labor-
atory assistance.
References
1 Hankey GJ, Eikelboom JW. Homocysteine and vascular 
disease. Lancet 1999;354:407–13.
2 Vollset SE, Refsum H, Tverdal A, Nygard O, Nordrehaug JE 
et al. Plasma total homocysteine and cardiovascular and 
noncardiovascular mortality: the Hordaland Homocysteine 
Study. Am J Clin Nutr, 2001;74:130–6.
3 Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, 
Upson B et al. A prospective study of plasma homocyst (e) ine 
and risk of myocardial infarction in US physicians. JAMA 
1992;268:877–81.
4 Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G 
et al. Low circulating folate and vitamin B6 concentrations: risk 
factors for stroke, peripheral vascular disease, and coronary 
artery disease. Circulation 1998;97:437–43.
5 Homocysteine Lowering Trialists’ Collaboration. Lowering 
blood homocysteine with folic acid based supplements: 
meta-analysis ofrandomised trials. BMJ 1998;316:894–8.
6 de Jong SC, Stehouwer CD, van den Berg M, Kostense PJ, 
Alders D et al. Determinants of fasting and post-methionine 
homocysteine levels in families predisposed to 
hyperhomocysteinemia and premature vascular disease. 
Arterioscler Thromb Vasc Biol 1999;19:1316–24.
7 Voutilainen S, Rissanen TH, Virtanen J, Lakka TA, 
Salonen JT. Low dietary folate intake is associated with an 
excess incidence of acute coronary events. The Kuopio ischemic 
heart diseases risk factor study. Circulation 2001;103 
(22):2674–80.
8 Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, 
Selhub J. Determinants of plasma total homocysteine 
concentration in the Framingham Offspring cohort. 
Am J Clin Nutr 2001;73 (3):613–21.
9 de Bree A, Verschuren WM, Blom HJ, Kromhout D. 
Association between B vitamin intake and plasma homocysteine 
concentration in the general Dutch population aged 20–65 y. 
Am J Clin Nutr 2001;73:1027–33.
10 Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power 
Shortage: clinical trials testing the ‘homocysteine hypothesis’ 
against a background of folic acid-fortified cereal grain flour. 
Ann Intern Med 2001;135:133–7.
11 Schnyder G, Roffi M, Pin R, Flammer Y, Lange H et al. 
Decreased rate of coronary restenosis after lowering of plasma 
homocysteine levels. N Engl J Med 2001;345:1593–600.
12 Vermeulen EG, Stehouwer CD, Twisk JW, van den Berg M, 
de Jong SC et al. Effect of homocysteine-lowering treatment 
with folic acid plus vitamin B6 on progression of subclinical 
atherosclerosis: a randomised, placebo-controlled trial. Lancet 
2000;355:517–22.
13 Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V. 
Mechanism of erythrocyte accumulation of methylation 
inhibitor S-adenosylhomocysteine in uraemia. Kidney Int 
1995;47:247–53.
14 Lee ME, Wang H. Homocysteine and hypomethylation: 
A novel link to vascular disease. Trends Cardiovasc Med 
1999;9:49–54.
15 Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR 
et al. Endothelial dysfunction elevation S-adenosylhomocysteine 
cystathionine {Beta}-synthase-deficient mice. Circ Res 
2001;88:1203–9.
16 Kerins DM, Koury MJ, Capdevila A, Rana S, Wagner C. 
Plasma S-adenosylhomocysteine is a more sensitive indicator 
of cardiovascular disease than plasma homocysteine. Am J Clin 
Nutr 2001;74:723–9.
17 Loehrer F, Angst C, Brunner F, Haefeli W, Fowler B. Evidence 
for disturbed S-adenosylmethionine: S-adenosylhomocysteine 
ratio in patients with end-stage renal failure: a cause for 
disturbed methylation reactions? Nephrol Dial Transplant 
1998;13:656–61.
18 Loehrer FM, Tschopl M, Angst CP, Litynski P, 
Jager K et al. Disturbed ratio of erythrocyte and plasma 
S-adenosylmethionine/S-adenosylhomocysteine in 
peripheral arterial occlusive disease. Atherosclerosis, 
2001;154:147–54.
19 Poirier LA, Wise CK, Delongchamp RR, Sinha R. 
Blood determinations of S-adenosylmethionine, 
S-adenosylhomocysteine, and homocysteine: 
correlations with diet. Cancer Epidemiol Biomarkers Prev, 
2001;10:649–55.
20 Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, 
Heine RJ. Peripheral arterial disease in relation to glycaemic 
level in an elderly Caucasian population: the Hoorn study. 
Diabetologia 1995;38:86–96.
21 Cockcroft DW, Gault MH. Prediction of creatinine clearance 
from serum creatinine. Nephron 1976;16:31–41.
22 Walma EP, Grundmeijer HG, Thomas S, Prins A, Hoogen JP, 
van den Laan JR et al. NHG-standaard hypertensie. Huisarts 
Wet 1997;40:598–617.
23 Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular 
Survey Methods. In: Geneva: World Health Organization;1982.
24 Shipchandler MT, Moore EG. Rapid, fully automated 
measurement of plasma homocyst (e) ine with the Abbott IMx 
analyzer. Clin Chem 1995;41:991–4.
25 Struys EA, Jansen EW, de Meer K, Jakobs C. Determination 
of S-adenosylmethionine and S-adenosylhomocysteine in 
plasma and cerebrospinal fluid by stable-isotope dilution 
tandem mass spectrometry. Clin Chem 2000;46:1650–6.
26 Ubbink JB, Serfontein WJ, de Villiers LS. Stability of pyridoxal-
5-phosphate semicarbazone: applications in plasma vitamin B6 
analysis and population surveys of vitamin B6 nutritional status. 
J Chromatogr 1985;342:277–84.
27 Clarke R, Daly L, Robinson K, Naughten E, Cahalane S et al. 
Hyperhomocysteinemia: an independent risk factor for vascular 
disease. N Engl J Med 1991;324:1149–55.
28 Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A 
et al. Total plasma homocysteine and cardiovascular risk profile. 
The Hordaland Homocysteine Study. JAMA 1995;274:1526–
33.
29 Graham IM, Daly LE, Refsum HM, Robinson K, 
Brattstrom LE et al. Plasma homocysteine as a risk factor for 
vascular disease. The European Concerted Action Project. 
JAMA 1997;277:1775–81.
30 Stehouwer CD, Weijenberg MP, van den Berg M, Jakobs C, 
Feskens EJ, Kromhout D. Serum homocysteine and risk of 
coronary heart disease and cerebrovascular disease in elderly 
men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 
1998;18:1895–901.
31 Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. 
Vitamin status and intake as primary determinants of 
homocysteinemia in an elderly population. JAMA 
1993;270:2693–8.
Metabolic precursors of homocysteine 25
© 2003 Blackwell Publishing Ltd, European Journal of Clinical Investigation, 33, 17–25
32 Brattstrom L, Lindgren A, Israelsson B, Andersson A, 
Hultberg B. Homocysteine and cysteine: determinants of 
plasma levels in middle-aged and elderly subjects. J Intern 
Med 1994;236:633–41.
33 Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, 
Zappia V. Metabolic consequences of folate-induced reduction 
of hyperhomocysteinemia in uraemia. J Am Soc Nephrol 
1997;8:1899–905.
34 Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D 
et al. Hyperhomocysteinemia confers an independent increased 
risk of atherosclerosis in end-stage renal disease and is closely 
linked to plasma folate and pyridoxine concentrations. 
Circulation 1996;94:2743–8.
35 van Guldener C, Stam F, Stehouwer CD. Homocysteine 
metabolism in renal failure. Kidney Int 2001;59(Suppl. 78):
S234–7.
36 Bostom AG, Lathrop L. Hyperhomocysteinemia in
 end-stage renal disease: prevalence, etiology, and potential 
relationship to arteriosclerotic outcomes. Kidney Int 
1997;52:10–20.
37 de Meer K, Stam F, van Guldener C. Hyperhomocysteinemia 
and cardiovascular disease. Am J Clin Nutr, 2001;73:992–
3.
38 Duerre JA, Miller CH, Reams GG. Metabolism of 
S-adenosyl-L-homocysteine in vivo by the rat. J Biol Chem 
1969;244:107–11.
39 Finkelstein JD. Pathways and regulation of homocysteine 
metabolism in mammals. Semin Thromb Hemost 
2000;26:219–25.
40 Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM et al. 
Fasting plasma homocysteine levels in the insulin resistance 
syndrome: the Framingham offspring study. Diabetes Care, 
2001;24:1403–10.
41 Blom HJ. Consequences of homocysteine export and oxidation 
in the vascular system. Semin Thromb Hemost 2000;26:227–32.
42 Surtees R. Demyelination and inborn errors of the single 
carbon transfer pathway. Eur J Pediatr 1998;157 (Suppl. 
2):S118–21.
43 van Asselt D, de Groot L, van Staveren W, Blom H, Wevers R 
et al. Role of cobalamin intake and atrophic gastritis in mild 
cobalamin deficiency in older Dutch subjects. Am J Clin Nutr 
1998;68:328–34.
44 Naurath HJ. Hyperhomocysteinemia in advanced age. Clin 
Chem Lab Med 2001;39:695–7.
45 Gonzalez-Gross M, Marcos A, Pietrzik K. Nutrition and 
cognitive impairment in the elderly. Br J Nutr 2001;86:313–21.
